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(57) ABSTRACT 
The invention is for a DNA vaccine expressing the hemag-
glutinin (HAI) gene of equine-2 influenza virus. By engi-
neering a stop codon within HAI, expression of HAI is 
ensured. By encapsulation of the DNA vaccine in liposome 
and by intranasal inoculation, it is sufficient to elicit protec-
tive immunity at a significantly lower dosage compared to a 
DNA vaccine expressing the full length HA gene. Lower 
dosage reduces the risk of induction of anti-DNA antibodies. 
Intranasal inoculation directly to the respiratory epithelial 
cells reduces the risk of DNA integration. The inventive 
vaccine is advantageous over current inactivated or live 
attenuated vaccines, as updating of the vaccine requires only 
the replacement of the encoding sequence with the new 
virus. 
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DNA VACCINE EXPRESSING HAl OF 
EQUINE-2 INFLUENZA VIRUS 
2 
influenza virus has diverged into multiple lineages [2], and 
that at least in North America, two evolutionary lineages 
circulate in alternate year [3]. 
Current EIV vaccines typically consist of formalin or CROSS REFERENCE TO RELATED 
APPLICATION 
This application claims the benefit of copending provi-
sional U.S. patent application Ser. No. 60/470,843, filed 
May 15, 2003, which application is incorporated herein by 
reference. 
5 ~-propiolactone inactivated whole viruses. The antigenic 
constituent is composed of equine influenza virus type 1 and 
type 2. A/Eq/Prague/56 is the only vaccine strain for type 1, 
whereas, type 2 constituents are the prototype A/Eq/Miami/ 
63 and a later strain such as A/Eq/Kentucky/81 or A/Eq/ 
BACKGROUND OF THE INVENTION 
1. Technical Field 
10 Fontainebleau/79. A recent meeting of WHO/OIE Consul-
tations on Control of Equine Influenza affirmed the earlier 
recommendations that vaccines should include both an 
"American" virus (A/Eq/Kentucky/94) and a "Eurasian" 
virus (A/Eq/Newmarket/2/93), and that the prototype A/Eq/ 
The present invention relates to vaccines for equine 
influenza virus, and, more particularly, to a DNA vaccine 
comprising the HAI encoding sequence of equine-2 influ-
enza virus which may be administered intranasally of a 
lower than typical dosage to elicit good mucosa! immunity. 
15 Miami/63 should be discontinued [4]. 
In recent prospective study, Morley et. al. [5] have shown 
that current commercial vaccines do not protect against virus 
infection, and only have marginal effect in the suppression 
of clinical symptoms. The lack of protection offered by 
2. Background 20 current commercial vaccines is due to one, or more, of a 
combination of the following factors: 
lack of imununogenicity; 
poor choice of vaccine strains; and/or 
eliciting an inappropriate immunity. 
The continued evolution of equine-2 influenza virus 
(H3N8) requires periodic updating of the vaccine strain to 
elicit protective immunity. However, there is a wide spec-
trum of vaccine strain choices among different vaccine 
manufacturers. 
Immunity generated by an earlier EIV will not be pro-
tective against later isolates due to a change of the antige-
nicity of HA, a result of amino acid substitutions ( antigenic 
drift). This characteristic of the virus is the major obstacle to 
a "fail-proof' effective vaccine. Updating of vaccine by 
Equine influenza virus (EIV) is the leading etiological 
agent for upper respiratory infections in horses. It has been 
implicated as the cause of epidemic outbreaks of respiratory 
disease in the horse for centuries. Spread of the virus is rapid 
and morbidity is extremely high. Infected horses develop 25 
typical "flu" symptoms: rapid onset of respiratory distress, 
coughing, fever, and mucous discharge. In rare cases, fatali-
ties result from secondary bacterial bronchial pneumonia. 
Although mortality rate is low, the effect of an equine 
influenza virus infection is significant. It is estimated that the 30 
suspension of horse racing in a 1992 Hong Kong outbreak 
resulted in a loss of US$120 million in revenue. The 
economic importance in other equine sports may be less, but 
outbreaks of equine influenza have interrupted international 
equine events on several occasions. An infected horse with-
out clinical signs but undergoing strenuous training may 
suffer long term consequences such as reduced pulmonary 
function. Clinically ill horses suffer the obvious disadvan-
tage of losing training time. 
35 replacing with more recent virus strains and in a more 
frequent intervals had been recommended [6]. Some manu-
facturers still keep outdated virus strains in their products. 
Although antibodies specific for equine influenza virus are 
elicited, however, these vaccines are problematic. First, 
Equine influenza virus is type A influenza virus, a member 40 serum antibody level serves as a poor indicator for protec-
tion. Second, as the circulating virus strains are sufficiently 
different from the vaccine strain, there is minimal cross-
reactivity. A "partial" immunity elicited by such outdated 
vaccine renders an infected host a non-symptomatic carrier, 
of Orthomyxoviridae. The viral genome consists of eight 
segments of negative-stranded RNA. The viral capsid is 
enclosed in a lipid envelope anchoring two surface viral 
glycoproteins: hemagglutinin (HA) and neuraminidase 
(NA). HA is believed to be the most antigenic viral protein 
ofEIV. HA has a molecular weight of approximately 77 kD. 
This viral protein is synthesized as HAO, and it is cleaved by 
protease action and subsequent reduction of the single 
disulfide bond into an amino terminal HAI portion (50 kD) 
and a carboxy terminal HA2 portion (27 kD). The HA2 50 
portion is anchored onto the lipid bilayer of a membrane, 
and HAI portion is bound to HA2 by non-covalent linkages. 
The hemagglutinin is involved in binding of the virus to the 
receptor at the host cell membrane, leading to the subsequent 
penetration and uncoating of the virus, hence initiating a 55 
viral replication. A major goal of vaccination is to induce 
immunity towards this viral encoded molecule. 
45 that is, the host is infected, but because of the partial 
immunity, clinical symptoms are suppressed. These infected 
hosts are not recognized, which facilitates the spread of the 
virus. 
There are two subtypes of equine influenza viruses. Type 
1, or equine- I influenza virus (H7N7), has not been isolated 
in developed countries for the last 15 years. Equine-2 60 
influenza virus (H3N8), however, continues to circulate 
around the world despite massive vaccination programs. The 
success of H3N8 virus is probably due to antigenic drift: 
sequential changes of the antigenicity of HA by amino acid 
substitution [1]. Recent isolates of equine-2 influenza 65 
viruses can be classified into either "American" lineage or 
"Eurasian" lineage. Furthermore, more recent equine-2 
Influenza virus initiates infection by attachment to the 
ciliated epithelial cells at the upper respiratory tract. There-
fore, mucosa! antibodies provide an effective defense 
against the virus. In fact, the importance of nasal antibodies 
in protection against equine influenza virus has been recog-
nized for many years. In a mouse model, it has been shown 
that transfer oflgA confers protection against influenza virus 
infection [7]. 
Whereas current vaccines elicit serum antibodies, none 
target mucosa! immunity. The correlation between serum 
antibodies level and vaccine efficacy is unclear, due to the 
lack of standardization of the measurement for both the 
antigen and the antibodies [8]. 
Several strategies, including the use of immune stimulat-
ing complexes (ISCOMs) [9], and by direct inoculation to 
the mucosa! area [10], have been used to boost mucosa! 
immune response to current vaccines for equine influenza 
virus. However, the results showed only limited improve-
ments using these strategies. 
US 7,244,435 B2 
3 
A recently licensed vaccine from Heska Corp. (Fort 
Collins, Colo.), based on recombinant cold-adapted (tem-
perature-sensitive mutant) and attenuated equine influenza 
virus, is an attempt to elicit mucosa! immunity. The vaccine 
4 
HAI is the immunogenic viral glycoprotein, as the antigenic 
sites are located in this portion of the viral protein. These 
results described above indicated that the expression of the 
HAI alone is sufficient to elicit protective immunity. Fur-
5 thermore, it was discovered that a much lower dosage of the 
HAI DNA vaccine is required to confer protection when 
compared to a DNA vaccine expressing the full length HA 
gene. 
is administered by intranasal inoculation to elicit mucosa! 
immunity. Direct inoculation of cold-adapted attenuated 
virus to the mucosa! site intranasally provides strong stimu-
lation of the mucosal-associated lymphoid tissues (MALT). 
Therefore, this vaccine is highly immunogenic and elicits 
mucosa! immunity. However, since the vaccine is based on 10 
recombinant virus through re-assortment, updating the vac-
cine requires re-engineering of the cold-adapted attenuated 
virus. All necessary safety and potency testing has to be 
done before the updated vaccine can be licensed. 
The field of DNA vaccine, or genetic immunization, is a 15 
rapidly emerging technology. It was a serendipitous discov-
ery that when a DNA plasmid containing the coding 
sequences of a protein is injected intramuscularly into a 
mouse, not only was the antigen expressed, but an immune 
response to the antigen was also elicited [11, 12]. It is 20 
believed that cells take up the DNA plasmid in vivo in a 
manner similar to that of a DNA transfection in vitro. The 
DNA plasmid does not replicate inside the host cells, but the 
encoded antigen is transcribed and translated by the host 
cell. The antigen is either expressed on the cell surface or 25 
secreted, and an immune response is elicited [13]. This new 
immunization methodolog has been shown to be effective by 
many investigators, and for a wide spectrum of infectious 
agents, including influenza virus in general [14], and specific 
for equine influenza virus [15]. It has been shown that a 30 
DNA vaccine expressing the HA gene of A/Eq/Kentucky/81, 
after administered via skin and mucosa, protected horses 
against a homologous virus challenge [15]. 
The DNA vaccine of the present invention possesses other 
advantages over current inactivated or live attenuated vac-
cines insofar as updating of the vaccine requires only the 
replacement of the antigen by inserting the HAI encoding 
sequence from a new virus. Moreover, the vaccine can be 
inoculated intranasally to target for mucosa! immunity. The 
vaccine also can be engineered to optimize the immunoge-
nicity of the expressed antigen. 
Another major advantage for the present discovery over 
prior art in that for the delivery of a DNA vaccine by gene 
gun, intramuscular, or intradermal injection, there is a risk of 
integration of the introduced DNA into the chromosome of 
the host cell. Mutations with adverse results or the devel-
opment of cancer are potential risks. With intranasal inocu-
lation after liposome encapsulation, the DNA vaccine is 
delivered directly to the epithelial cells of the respiratory 
tract. Since epithelial cells are replaced at a high rate, the 
risk of chromosomal integration is significantly diminished 
Furthermore, as described below, the use ofHAl alone (with 
an engineered stop codon) reduces the dosage required, 
further reducing the risk of integration as well as reducing 
the risk of eliciting anti-DNA antibodies. 
Thus, in one embodiment of the present invention there is 
provided a DNA vaccine composition comprising DNA 
encoding sequences for HAI of equine-2 influenza virus, or 
epitopes thereof, wherein the vaccine further comprises a 
pharmacologically acceptable carrier or diluent. The HAI 
encoding sequence may be selected from known strains of 
equine-2 influenza virus, and in one embodiment is prefer-
ably from strain A/Eq/Kentucky/98. In a specific example, 
the HAI encoding sequence comprises the nucleotide 
sequence of SEQ ID NO: 1. 
In the patent art, vaccines and methodologies against EIV 
are described in U.S. Pat. Nos. 6,482,414; 6,436,408; 6,398, 35 
774; 6,177,082; 6,045,790; 4,920,213; 4,693,893; 4,689, 
224; 4,683,137; 4,631,191; and 4,619,827, all of which are 
incorporated herein by reference. U.S. Pat. Nos. 4,920,213 
and 4,631,191 are directed to recombinant vaccines for 
immunizing horses against equine influenza virus. DNA 40 
sequences encoding the HA and NA glycoproteins from two 
strains were used to construct vaccinia carried vaccines, to 
design synthetic peptides for primer and booster adminis-
tration, and to permit recombinant synthesis of HA and/or 
NA protein based vaccines. 
In another embodiment of the invention, the DNA vaccine 
is combined with an adjuvant in order to enhance the 
immune response and/or to promote the proper rate of 
45 
absorption following inoculation. 
An ideal vaccine for equine influenza virus, by addressing 
the above deficiency of current vaccines, should be highly 
immunogenic, elicit a mucosa! immunity, and be amenable 
In a further embodiment of the invention, there is pro-
vided a method for inducing an immune response in an 
equine to prevent or reduce the severity of equine influenza 
virus infection, the method comprising administering to an to easy "updating". 
SUMMARY OF THE INVENTION 
50 at-risk animal an effective immunizing amount of the inven-
tive vaccine, alone or in combination with an adjuvant or 
additional antigenic components or encoding sequences, to 
provide a means to control equine influenza virus infections, 
wherein the vaccine further comprises a pharmacologically 
The present invention is based on the discovery that a 
DNA vaccine containing the encoding sequence for the HAI 
segment of the HA glycoprotein from equine-2 influenza 
virus confers protective immunity when administered intra-
nasally. The DNA vaccine expressing HAI was encapsu-
lated into a liposome vector and inoculated into the nasal 
cavity of Balb/c mice. After two booster vaccinations, the 
mice were challenged with a sub-lethal dose of infectious 60 
homologous virus. For the non-immunized control group, a 
7.9% maximum weight loss was observed. For the DNA 
vaccine immunized group and for the positive control group 
(immunized with inactivated homologous virus), the 
observed weight losses were 1.8% and 1.6%, respectively. In 65 
addition, viral specific IgG and IgA antibodies were elicited. 
The precursor for the HA is cleaved into HAI and HA2. 
55 acceptable carrier or diluent. 
Preferably, the DNA vaccine includes a vector, and most 
preferably, the DNA is encapsulated into liposomes and 
delivered intranasally into the respiratory tract of the subject 
in order to elicit a good mucosa! immunity. 
A better understanding of the present invention and its 
objects and advantages will become apparent to those skilled 
in this art from the following detailed description wherein 
there is described only the preferred embodiment of the 
invention, simply by way of illustration of the best mode 
contemplated for carrying out the invention. As will be 
realized, the invention is capable of modifications in various 
obvious respects, all without departing from the scope and 
US 7,244,435 B2 
5 
spirit of the invention. Accordingly, the description should 
be regarded as illustrative in nature and not as restrictive. 
BRIEF DESCRIPTION OF THE DRAWINGS 
6 
York/99, A/Eq/Oklahoma/00, and, more preferably, from 
strain A/Eq/Kentucky/98. Most preferably, the HAI encod-
ing sequence comprises the nucleotide sequence of SEQ ID 
NO: 1 from Kentucky/98. But, as contemplated herein, the 
FIG. 1 is a schematic map for example embodiments of 
the inventive DNA vaccine. The HAI gene of A/Eq/Ken-
tucky/98 is inserted into a eukaryotic expression vector: 
either pcDNA3.1N5-His-TOPO or pVAXl, both being 
available from Invitrogen (Carlsbad, Calif.). Of the con-
structed vectors expressing the HAI of equine-2 influenza 
virus (A/Eq/Kentucky/98 as an example), pTOPO/KY98-6 
utilizes the stop codon provided by the vector, whereas for 
pTOPO/KY98-ll and pVAX/KY98-11, a stop codon is 
provided by the reverse primer during PCR. Insert: Amino 
acid sequence for the HAI of A/Eq/Kentucky/98 (GenBank 
Accession No. AF197241). The signal peptide is displayed 
5 invention includes the HAI encoding sequence of other 
strains and analogs, fragments, mutants, substitutions, syn-
thetics, or variants thereof that effectively encode HAI, its 
epitopes, and/or mimetics. (See, for example, reference [2] 
below, Tables 1 and 3, incorporated herein by reference, for 
10 a listing of various virus strains with their corresponding 
GenBank accession numbers, from which the nucleotide 
sequences of the HAI gene may be obtained). As a result, 
the invention encompasses DNA sequences which encode 
for and/or express in appropriate transformed cells, proteins 
in the first row. Boxed sequences: Antigenic sites A 
(132-146); site B (187-199); site C (51-55, 273-278); and 
site D (171-174, 209-217, 241-246). V5: V5 epitope; His6: 
15 which may be the full length antigen, antigen fragment, 
antigen derivative or a fusion product of such antigen, 
antigen fragment or antigen derivative with another protein. 
The invention also contemplates a DNA vaccine having an 
isolated recombinant strain with the immunogenic charac-
Six-histidine tag; BGHpA: Bovine Growth Hormone poly-
adenylate signal. 
20 teristics of contemporary strains, including the strains herein 
described. 
FIG. 2 is a graph reflecting experimental results of the 
described weight loss study. The percentage weight loss of 
infected mice is plotted against the days after virus cha!- 25 
lenge. Inactivated KY98: positive control group; PBS and 
pGFP: negative control groups. pTOPO/KY98-6 and 
pTOPO/KY98-ll: DNA vaccine immunized groups. The P 
values for Student's t-test between PBS control group and 
pTOPO/KY98-6 and pTOPO/KY98-ll immunized groups 30 
are 0.001 and 0.006, respectively. 
FIG. 3A is a graph reflecting experimental results of the 
described ELISA for serum viral specific IgG. Boosters were 
administrated on day 21 and day 35. Virus challenge was 
administered 15 days after the second booster on day 50, and 35 
15 days post infection, as indicated by*. 
FIG. 3B is another graph reflecting experimental results 
of the described ELISA for serum viral specific IgA. Boost-
ers were administrated on day 21 and day 35. Virus chal-
lenge was administered 15 days after the second booster on 40 
day 50, and 15 days post infection, as indicated by*. 
DETAILED DESCRIPTION OF THE 
INVENTION 
As defined herein an "isolated" DNA is one which is 
substantially separated from other cellular components 
which naturally accompany a native sequence. The term 
embraces a nucleic acid sequence that has been removed 
from its naturally occurring environment, and includes 
recombinant or cloned DNA isolates and chemically syn-
thesized analogs or analogs biologically synthesized. 
The term "vector" refers generally to any DNA vaccine 
vector, numerous ones of which are known in the art, that by 
itself is "inert" (not eliciting immunity to itself), can easily 
be introduced to the recipient (to elicit immunity to the 
insert), and does not integrate into the host chromosome. 
Reference is made to U.S. Pat. Nos. 6,468,984 and 6,339, 
068, which patents are incorporated herein and which delin-
eate various vectors and delivery systems known in the art. 
Preferred vectors are the pVAXl and pcDNA3.1/V5-His-
TOPO eukaryotic expression vectors commercially avail-
able from Invitrogen, Carlsbad, Calif. 
The vaccine of the present invention may include nucleic 
acid sequences that regulate the expression of the HAI 
encoding sequence to which it is operatively linked. Expres-
sion control sequences are operatively linked to a nucleic 
acid sequence when the expression control sequences con-
Before explaining the present invention in detail, 1t 1s 
important to understand that the invention is not limited in 
its application to the details of the construction illustrated 
and the steps described herein. The invention is capable of 
other embodiments and of being practiced or carried out in 
a variety of ways. It is to be understood that the phraseology 
and terminology employed herein is for the purpose of 
description and not of limitation. 
45 trol and regulate the transcription and, as appropriate, trans-
lation of the nucleic acid sequence. Thus expression control 
sequences can include appropriate promoters, enhancers, 
transcription terminators, a start codon (i.e., ATG) in front of 
a protein-encoding gene, splicing signal for intrans, main-
50 tenance of the correct reading frame of that gene to permit 
proper translation of mRNA, and stop codons. 
The inventive vaccine further comprises a pharmacologi-
cally acceptable carrier or diluent. Suitable carriers for the 
vaccine are well known to those skilled in the art and include 
but are not limited to proteins, sugars, etc. Such carriers may 
be aqueous or non-aqueous solutions, suspensions, and 
emulsions. Examples of non-aqueous carriers are propylene 
glycol, polyethylene glycol, vegetable oils such as olive oil, 
and injectable organic esters such as ethyl oleate. Aqueous 
60 carriers include water, alcoholic/aqueous solutions, emul-
sions or suspensions, including saline and buffered media. 
Parenteral vehicles include sodium chloride solution, Ring-
er's dextrose, dextrose and sodium chloride, lactated Ring-
er's or fixed oils. Intravenous vehicles include fluid and 
The present invention provides a novel DNA vaccine and 
method designed to protect against EIV. The invention is 55 
directed to DNA-mediated vaccination and it preferably 
involves the direct introduction via a vector of isolated DNA 
encoding HAI or epitopes thereof selected from any con-
temporary strain, which is then expressed within cells of the 
inoculated equid. The inventive vaccine may be adminis-
tered alone or in combination with additional antigenic 
components or skilled in the art. 
Preferably, the isolated HAI encoding sequence is 
selected from the group consisting of strains A/Eq/Ken-
tucky/98, A/Eq/Miami/63, A/Eq/Kentucky/81, A/Eq/Fon- 65 
tainebleau/79, A/Eq/Saskatoon/90, A/Eq/Kentucky/92, 
A/Eq/Kentucky/94 and A/Eq/Newmarket/2/93, A/Eq/New 
nutrient replenishers, electrolyte replenishers such as those 
based on Ringer's dextrose, and the like. Preservatives and 
other additives may also be present, such as, for example 
US 7,244,435 B2 
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antimicrobials, antioxidants, chelating agents, inert gases 
and the like. Preferred preservatives include formalin, 
thimerosal, neomycin, polymyxin B and amphotericin B. 
The term "adjuvant" refers to a compound or mixture that 
enhances the immune response and/or promotes the proper 5 
rate of absorption following inoculation, and, as used herein, 
encompasses any uptake-facilitating agent. Acceptable adju-
vants include, but are not limited to, complete Freund's 
adjuvant, incomplete Freund's adjuvant, saponin, mineral 
gels such as aluminum hydroxide, surface active substances 10 
such as lysolecithin, pluronic polyols, polyanions, peptides, 
oil or hydrocarbon emulsions, keyhole limpet hemocyanins, 
dinitrophenol, and others. A preferred adjuvant is the 
METASTIM® adjuvant of Fort Dodge Animal Health. 
The method comprises administering to the animal an 15 
effective immunizing dose of the vaccine of the present 
invention. For purposes of this invention, an "effective 
immunizing amount" of the vaccine of the present invention 
is at least 0.001 µg DNA per kilogram of body weight, and 
preferably falls within the range of 0.001 µg DNA per 20 
kilogram of body weight to 0.01 µg DNA per gram of body 
weight. The vaccine is preferably administered intranasally, 
after encapsulation in liposomes/adjuvants as described 
above, to elicit the desired mucosa! immunity, but may 
otherwise if desired be administered by any of the methods 25 
well known to those skilled in the art, for example, by 
intramuscular, subcutaneous, intraperitoneal, intravenous, 
orally, intradermal, or ocularly. 
The present invention is further illustrated by the follow-
ing example, which is intended to aid understanding of the 30 
invention but is not intended, and should not be construed, 
to limit in any way the invention as set forth in the claims 
which follow thereafter. 
8 
pTOPO/KY98-ll (with a stop codon built in the reverse 
primer). Expression of the HAI was confirmed by PCR and 
by western blot hybridization, using convalescent serum 
from infected horses. An additional clone, constructed by 
restriction endonuclease digestion of pTOPO/KY98-l 1 with 
BamHI and XhoI to excise the HAI insert, followed by 
ligation of the insert into the BamHI and XhoI site of 
pVAXl, resulting in the creation ofpVAX/KY89-ll. 
DNA Immunization and Virus Challenge: 
Plasmid DNA was amplified in E. coli, extracted, and 
purified using a MaxiPrep Kit (Qiagen, Valencia, Calif.). 
The concentration and purity of the DNA preparation was 
determined by spectroscopic analysis, and by restriction 
endonuclease digestion followed by agarose gel electro-
phoresis. For DNA vaccination, the DNA preparation was 
diluted in Dulbecco's Modified Eagle's Medium (DMEM) 
(Roche Applied Science, Indiapolis, Ind.) to 20 µg/ml. The 
suspension was mixed with an equal volume of lipo-
fectamine (Roche) solution (at 20 µg/ml in DMEM) for 20 
min at room temperature before inoculation. 
Female Balb/c mice (Jackson Laboratories, Bar Harbor, 
Me.), 4 to 8 weeks old, were divided into groups of four. For 
intranasal inoculation, each mouse was anesthetized with 
isoflurane (forane, l-choro-2,2,2-trifluoroethyldifluorom-
ethyl ether). With a micropipette, 25.0 µI of the DNA 
suspension (a dosage of0.01 µg/g body weight) was instilled 
into the nasal cavity. Two groups of mice received the DNA 
vaccine, one with pTOPO/KY98-6, and a second group with 
pTOPO/KY98-ll. Two negative control groups were 
included. One inoculated with phosphate-buffered saline 
(PBS) and a second inoculated with a non-related plasmid 
DNA vector expressing a green fluorescence protein (pGFP/ 
Green Lantern, Gibco, BRL). An additional group was 
EXAMPLE 
Materials and Methods 
35 
inoculated with uv-inactivated A/Eq/Kentucky/98 at a dos-
age of 8.0 HA unit (equivalent to 1.6xl07 egg infectious 
dose 50% [EID50], or lxl06 plague forming unit [pfu]) per 
mouse as a positive control group. Two booster vaccinations, 
at the same dosage, were administered on day 21 and on day 
Virus and Virus Amplification: 
Equine-2 influenza virus, A/Eq/Kentucky/98, was a gen-
erous gift from Dr. Thomas Chambers, University of Ken-
tucky. Virus amplification and characterization was per-
formed as previously described [2]. Briefly, the virus was 
cultivated in 9 to 11 day-old embryonated chicken eggs at 
37° C. for 72 hr. The allantoic fluid was harvested as 
described by Mahr et al. [16]. After clarification by cen-
trifugation at 1000 g for 15 min, virus titer was determined 
by a hemagglutination assay using chicken erythrocytes. 
40 
35. Virus challenge was given at day 50 (15 days after the 
second booster). Each mouse was inoculated intranasally 
with 16 HA unit (equivalent to 3.2xl07 EID50 or 2xl06 pfu) 
of the homologous virus (A/Eq/Kentucky/98), and body 
weights were measured for each mouse for the next 10 days. 
45 
In addition, to investigate if DNA vaccination elicits 
specific antibodies, sera were collected by retro-orbital 
bleeding (after anesthesia) at day 0, 21, 35, 50 and 65. These 
time points correspond to "pre-bled", first and second 
booster vaccination, virus challenge, and 15 days post-
Construction of DNA Vaccine: 50 challenge, respectively. 
To synthesize the DNA template for cloning, the HAI 
open reading frame was prepared by the reverse-transcrip-
tion and the polymerase chain reaction (RT-PCR). Viral 
RNA was extracted, and cDNA synthesized using the uni-12 
primer (5'AGCAAAAGCAGG3') (SEQ. ID NO: 2) and 55 
MMLV reverse transcriptase (Stratagene, La Jolla, Calif.). 
The template were synthesized by PCR using primers EH3-
29+ (5'CATGAAGACAACCATTATTTT3') (SEQ. ID NO: 
3) and EH3-1061-(5'TCTGATTTGCTTTTCTGGTA3') 
(SEQ. ID NO: 4) or EH3-29+ and EH3-1061STOP 60 
(5'TCATCTGATTTGCTTTTCTGGTA3') (SEQ. ID NO: 5). 
PCR was carried out at 95° C., 1 min, 45° C., 2 min, and 72° 
C., 3 min. for 25 cycles, and using Taq DNA polymerase 
(Stratagene, La Jolla, Calif.). The PCR product was ligated 
into pcDNA3.1/V5-His-TOPO eukaryotic vector, according 65 
to manufacturer's instructions. Two clones were identified 
and used in subsequent experiments: pTOPO/KY98-6, and 
Titration of Viral Specific IgG and IgA: 
ELISA plates were prepared by using a suspension of 
sucrose-gradient purified homologous equine influenza 
virus, A/Eq/Kentucky/98. The virus was diluted in 50 mM 
NaHCO
3 
buffer to 0.6 HA unit/ml, and 100 µI of this virus 
suspension was added to each well of a ELISA plate. The 
plates were left at room temperature for 24 hr for the antigen 
to be "coated" onto the plate. A blocking buffer [PBS 
containing 2.0% bovine serum albumin (BSA) and 1.0% 
skim milk] was added after the ELISA plates were washed 
three times with PBS, and incubated at room temperature for 
a further hour. One hundred microiter of diluted mouse sera 
(1:10 in PBS with 2.0% BSA) were added, after washing 
again with PBS, and incubated as above. Following incu-
bation at room temperature for 1 hr and washing with PBS, 
100 µI of diluted (1:2000 in PBS with 2% BSA) alkaline 
phosphatase-conjugated rabbit anti-murine IgG or IgA anti-
US 7,244,435 B2 
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serum (Sigma, St. Louis, Mo.) was added. After incubation 
at room temperature for 1 hr, the plates were washed again 
with PBS, and 100 µl of "substrate" was added [1.0 mg/ml 
of 4-nitrophenyl phosphate solution (pNPP), Sigma]. After 
incubation at room temperature for 2.5 hr, absorption at 405 5 
nm was determined using a microplate reader (Biotek Instru-
ments, Winooski, Vt.). All serum samples were assayed in 
triplicates. The mean absorption for the "pre-bleed" serum 
was subtracted from the adsorption values of the immune 
sera, and the results were expressed as an increase in optical 10 
density at 405 nm (llO.D. 405). 
Results 
10 
DNA vaccine vectors, they elicited a similar protective 
immunity to that elicited by inactivated virus. 
Titration of Viral Specific IgG and IgA: 
The result of ELISA is shown in FIGS. 3A and 3B. As 
described above, the O.D. 405 nm of control sera were 
deduced, and the result is expressed as the mean of an 
increased O.D. 405 nm plus the standard error for triplicate 
wells. Booster vaccinations were administered on days 21 
and 35, and the mice were challenged with live virus on day 
50. Sera were also tested 15 days after virus challenge. 
For the mice immunized with uv-inactivated virus (posi-
tive control group), viral specific IgG was detected as early 
as on day 21, with an increased O.D. of 0.49. (FIG. 3A). 
Validation for the DNA Vaccine: 
Three DNA vaccine vectors were constructed and iden-
tified. They were characterized both by PCR and by restric-
tion digest. PCR and restriction analysis indicated a correct 
size of insert (approximately 1.0 kb) and correct orientation 
with respect to the CMV promoter in the pcDNA3.1N5-
His-TOPO and pVAXl vector, as shown in FIG. 1. The stop 
codon contained in the EH3-1061STOP primer causes the 
translation of the HAI gene insert to terminate before the 
sequences encoding the V5 epitope and the His6 tag for the 
vector pTOPO/KY98-ll. pVAX/KY98-ll utilizes the 
"built-in" stop codon within the HAI. Whereas for the 
vector pTOPO/KY98-6, termination of the insert relies on 
the stop codon in the vector, hence the product is linked to 
the V5 and His6 "tag" at its carboxy-terminus. Western blot 
hybridization using convalescent horse serum demonstrated 
that both vectors, after transfection into MDBK cells, pro-
duced a protein of approximately 50 KD, consistent with the 
correct expression of the HAI antigen ( data not shown). 
15 
However, IgA was detected only marginally, with an 
increased O.D. of 0.09 (FIG. 3B). On day 35, two weeks 
after the first booster, IgG level was increased by more than 
3-fold. Interestingly, instead of a further increase by the 
second booster vaccination, the IgG level on day 50 was 
20 
actually lower than that of on 35. However, after live virus 
challenge, as expected, there was an increase in IgG level, 
from O.D. 1.2 to about O.D. 1.7. For IgA, a similar pattern 
was observed. However, the levels were significantly lower. 
For the DNA vaccine immunized groups, both have 
25 
detectable viral specific IgG and IgA responses and the 
pattern is similar to that elicited by uv-inactivated virus. 
After first booster vaccination, there was an increased of 1.5 
to 2-fold for IgG and IgA (for pTOPO/KY98-6 vaccinated 
group, an increased from 0.31 to 0.55, and from 0.17 to 0.36, 
30 
respectively). Similarly, the second booster vaccination did 
not raise the levels of IgG or IgA further. However, IgG was 
increased by more than 3-fold after virus challenge. IgA was 
also elevated, although less than 2-fold. 
Interestingly, for the negative control group vaccinated 
DNA Immunization and Virus Challenge: 35 with a non-specific vector, pGFP, viral specific IgG or IgA before virus challenge was "detected". However, an increase 
ofless than 0.2 O.D. may be a non-specific result. After virus 
challenge, both IgG and IgA were detected, as expected in 
a primary infection (FIG. 3A and FIG. 3B). Similarly, for the 
Since mice do not develop obvious respiratory symptoms 
characteristic for influenza virus infection, a weight loss 
model was employed to evaluate the efficacy of the DNA 
vaccine. Body weight loss after virus challenge and the 
subsequent recovery were taken as the criteria to compare 
the severity of symptoms, and hence the level of protection 
conferred by the DNA vaccine. Each mouse was weighed 
daily after virus challenge, and the result was expressed as 
the percentage of body weight change to that of prior to the 
virus challenge. The mean body weight loss plus the stan- 45 
dard error of the mean (SEM) for each group was plotted 
against days post-infection is shown in FIG. 2. 
40 
PBS immunized group, the O.D. for IgG and IgA at 15 days 
post virus challenge were 1.68±0.12 and 0.35±0.03, respec-
tively (data not shown). 
It was noticeable that the vaccinated mice (with both 
DNA vaccine vectors or with uv-inactivated virus) devel-
oped little or no clinical symptoms such as anorexia, "fluffy 50 
coat" appearance ( an indicator of pyrexia ), and inactivity 
after virus challenge. For the negative control group immu-
nized with PBS, they showed signs of severe infection, and 
they started to loose weight on day 1, with a maximum of 
Discussion 
Less DNA for the Protection 
Influenza virus has been used as a model organism in the 
study of DNA vaccines. As early as 1993, it has been shown 
that an HA expressing plasmid could confer protection 
against influenza [17] [18] [19] [13]. However, these inves-
tigations were done using a DNA construct consisted of the 
full length HA gene. The HA is the viral glycoprotein for 
receptor binding and membrane fusion, and the bulk of the 
HA2 molecule is an integral membrane protein. The hemag-
glutinin is synthesized as an HAO precursor, followed by 
proteolytic cleavage into HAI and HA2. HAI contains the 
major protective antigenic sites, and it is non-covalently 
linked to HA2 which is anchored into the viral envelope 
[20]. We report here that, with the expression ofHAl alone 
7 .9% weight loss at day 8 after virus challenge. The weight 55 
loss persisted for more than 10 days. The second negative 
control group (pGFP) also showed significant weight loss 
for the first 3 days (4.6% body weight), then started to 
recover. In contrast, none of the immunized groups showed 
any significant body weight loss. 
Paired Student's t-tests were performed on the changes in 
body weight to determine if there is any statistical signifi-
cance. The P values for comparing the pTOPOKY98-6 and 
pTOPOKY98-ll to the PBS control group were 0.001 and 
0.006, respectively. This is comparable to the P values of 65 
0.0001 between the positive control group (immunized with 
uv-inactivated virus) and the PBS group. Therefore, for both 
60 is sufficient to elicit protective immunity. Omission of the 
HA2 may circumvent a requirement for enzymatic process-
ing, as a tissue specific protease is required to cleave the 
precursor HAO into HAI and HA2. Furthermore, in the 
absence of HA2, synthesized HAI will not be membrane 
bounded, and hence allowing more HAI molecules to be 
released and taken up by antigen presenting cells to elicit a 
stronger immune response. Therefore, the immunogenicity 
US 7,244,435 B2 
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of this DNA vaccine is significantly enhanced. In addition, 
a lower quantity of this DNA vaccine is required for immu-
nization. Protective immunity was elicited by as low as 0.01 
µg DNA per gram of body weight, which is 10-fold less than 
that reported by Wong et al. [21], and is a 2-fold less than 5 
used by a gene gun inoculation [17]. It should be noted that, 
if the same dosage as reported by Fynan et al. were applied 
for a horse with an average size of 400 Kg, the amount of 
DNA required would be 4.0 mg per inoculation. 
Furthermore, by encapsulating a DNA vaccine, immuni- 10 
zation with less DNA, and by inoculation at mucosa! site, the 
risk of potential DNA integration into somatic or germline 
cells is significantly reduced. 
12 
even though the P value is significant. This "earlier recov-
ery" is not due to specific immunity, as no viral specific 
antibodies were detected prior to virus challenge (the absor-
bance values were bordering at the background level). It is 
well known that certain motifs in a DNA vaccine vector 
elicit non-specific immunity. Introduction of liposomes at 
the mucosa! site might also induce a non-specific immunity. 
Additional Data 
To establish a protocol for mucosa! immunization in the 
horse, several horses were inoculated intranasally with the 
DNA vaccine of the present invention, and nasal washings 
collected several weeks later revealed positive signals for Role of IgA 
Influenza virus initiates infection at the respiratory tract. 15 viral specific antibodies. 
As many previous studies have shown, mucosa! immunity is 
important in protection against influenza virus or other 
respiratory infections [22, 23]. Secretory IgA plays a sig-
nificant role in mucosa! immunity. It has been shown that 
20 IgA is responsible for the protection against influenza virus 
infection [24]. Furthermore, passive transfer of influenza-
specific IgA protects the recipient mice from influenza virus 
infection [7]. Lunn et al. had investigated a DNA vaccine for 
equine influenza virus in ponies [15]. Using a gene gun, a 
25 DNA vaccine was delivered to several mucosa! sites, includ-
ing the tongue, conjunctiva, and the third eyelid. In each 
case, a strong IgG response was stimulated. However, a poor 
IgA response was elicited. 
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SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 5 
<210> SEQ ID NO 
<211> LENGTH: 1061 
<212> TYPE: DNA 
<213> ORGANISM: A/Eg/Kentucky/98 
<400> SEQUENCE: 
agcaaaagca ggggatattt ctgtcaatca tgaagacaac cattattttg atactactga 60 
cccattgggt ctacagtcaa aacccaacca gtggaaacaa cacagccaca ttatgtctgg 120 
gacaccatgc agtagcaaat ggaacattgg taaaaacaat aactgatgac caaattgagg 180 
tgacaaatgc tactgaatta gttcagagca tttcaatagg gaaaatatgc aacaactcat 240 
ataaagttct agatggaaga aattgcacat taatagatgc aatgctagga gacccccact 300 
gtgatgtctt ccagtatgag aattgggacc tcttcataga aagaagcagc gctttcagca 360 
attgctaccc atatgacatc cctgactatg catcgctccg gtccattgta gcatcctcag 420 
gaacattaga attcacagca gagggattca catggacagg tgtcactcaa aacggaagaa 480 
gtggagcctg caaaagggga tcagccgata gtttctttag ccgactgaat tggctaacaa 540 
aatctggaaa ctcttacccc acattgaatg tgacaatgcc taacaataaa aatttcgaca 600 
aactatacat ctgggggatt catcacccga gctcaaacca acagcagaca gaattgtaca 660 
tccaagaatc aggacgagta acagtctcaa caaaaagaag tcaacaaacg atagtcccta 720 
atatcggatc tagaccgtgg gttaggggtc aatcaggcag gataagcata tactggacca 780 
ttgtaaaacc tggagatatc ctaatgataa acagtaatgg caacttagtt gcaccgcggg 840 
gatattttaa attgaaaaca gggaaaagct ctgtaatgag atcagatgca cccatagaca 900 
tttgtgtgtc tgaatgtatt acaccaaatg gaagcatccc caacgacaaa ccatttcaaa 960 
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-continued 
atgtgaacaa agttacatat ggaaaatgcc ccaagtatat caggcaaaac actttaaagc 1020 
tggccactgg gatgaggaat ataccagaaa agcaaatcag a 1061 
<210> SEQ ID NO 2 
<211> LENGTH: 12 
<212> TYPE: DNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 2 
agcaaaagca gg 
<210> SEQ ID NO 3 
<211> LENGTH: 21 
<212> TYPE: DNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 3 
catgaagaca accattattt t 
<210> SEQ ID NO 4 
<211> LENGTH: 20 
<212> TYPE: DNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 4 
tctgatttgc ttttctggta 
<210> SEQ ID NO 5 
<211> LENGTH: 23 
<212> TYPE: DNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 5 
tcatctgatt tgcttttctg gta 
What is claimed is: 
1. A vaccine for equine influenza virus, comprising: 
an effective immunizing amount of an isolated DNA, the 
isolated DNA comprising sequences that encode at 
least a fragment of an HAI protein, wherein DNA 
encoding HA2 is absent, the sequences being from a 
strain of equine-2 influenza virus; and a pharmacologi-
cally acceptable carrier or diluent. 
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5. The vaccine according to claim 1, further comprising 
one or more of the group consisting of additional antigenic 
50 components, encoding sequences for additional antigenic 
components, and other vaccines. 
6. The vaccine according to claim 1, further comprising a 
vector containing the sequences that encode at least a 
fragment of an HAI protein, wherein DNA encoding HA2 
55 is absent. 
2. The vaccine according to claim 1, wherein the strain of 
equine-2 influenza virus is selected from the group consist-
ing of A/Eq/Kentucky/98, A/Eq/Miami/63, A/Eq/Kentucky/ 
81, A/Eq/Fontainebleau/79, A/Eq/Kentucky/94, A/Eq/New-
market/2/93, A/Eq/New York/99, and A/Eq/Oklahoma/ 60 
2000. 
7. The vaccine according to claim 6, wherein the vector is 
a eukaryotic expression vector. 
8. The vaccine according to claim 7, wherein the vector is 
selected from the group consisting of pcDNA3.1/V5-His-
TOPO and pVAXl. 
3. The vaccine according to claim 1, wherein the strain is 
A/Eq/Kentucky /98. 
4. The vaccine according to claim 1, wherein the 
sequences that encode at least a fragment of an HAI protein, 
wherein DNA encoding HA2 is absent, comprise the nucle-
otide sequence of SEQ ID NO: 1. 
9. The vaccine according to claim 1, further comprising an 
adjuvant. 
10. The vaccine according to claim 9, wherein the adju-
65 vant is selected from the group consisting of complete 
Ereund's adjuvant, incomplete Freund's adjuvant, saponin, 
mineral gels, surface active substances, pluronic polyols, 
US 7,244,435 B2 
17 
polyanions, peptides, oil or hydrocarbon emulsions, keyhole 
limpet hemocyanins, and dinitrophenol. 
11. The vaccine according to claim 1, further comprising 
a liposome into which the sequences that encode at least a 
fragment of an HAI protein, wherein DNA encoding HA2 5 
is absent is encapsulated. 
12. A method of inducing an immune response against 
equine influenza virus, comprising administering to an equip 
an effective immunizing amount of the vaccine of claim 1. 
13. The method according to claim 12, further comprising 10 
the steps of inserting the sequences that encode at least a 
fragment of an HAI protein, wherein DNA encoding HA2 
is absent into a vector and delivering the vaccine intranasally 
into the respiratory tract. 
14. The method according to claim 13, wherein the vector 15 
is a eukaxyotic vector. 
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15. The meted according to claim 14, wherein the vector 
is selected from the group consisting of pcDNA3.1/V5-His-
TOPO and pVAXl. 
16. The method according to claim 14, wherein the vector 
is a liposome. 
17. The method according to claim 12, wherein the 
vaccine is administered at a dosage of at least 0.01 µg DNA 
per gram of body weight. 
18. The method according to claim 12, wherein the 
vaccine is administered at a dosage falling within the range 
of 0.001 µg DNA per kilogram of body weight to 0.01 µg 
DNA per grain of body weight. 
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